For the roughly 10% of cancer patients harboring inherited germline mutations, prevention has long meant surveillance and early detection. A sweeping review in the International Journal of Cancer reframes this population not merely as high-risk individuals to monitor, but as a living laboratory for intercepting cancer before it starts — a shift with profound implications for both rare-syndrome patients and the broader population.

The analysis synthesizes advances across several convergent fronts. Long-read sequencing and tumor-normal paired testing are now resolving structural and noncoding variants that standard panels miss, meaningfully expanding the diagnostic yield in cancer predisposition syndromes (CPS). Newborn screening — exemplified by Brazil's population-level program targeting the TP53 R337H variant — is demonstrating both clinical utility and cost-effectiveness, pushing the intervention window to birth. Liquid biopsy approaches capable of detecting circulating tumor signals before radiologic findings appear are positioned to complement or eventually replace imaging-heavy surveillance protocols. On the interception side, two pharmacologic strategies stand out: metformin in Li-Fraumeni syndrome (driven by TP53 dysfunction and metabolic vulnerability) and aspirin in Lynch syndrome (exploiting prostaglandin-mediated tumor promotion). Immunoprevention strategies round out the pipeline, though the excerpt stops short of detailing specific agents.

This review is confirmatory rather than paradigm-shifting in isolation, but its aggregation of evidence across genomics, surveillance, and chemoprevention makes it a useful orienting document. The critical limitation is that most interception data remain early-phase or observational; the Lynch–aspirin connection is the most robustly replicated, while metformin in Li-Fraumeni is still accruing trial evidence. The broader value lies in the translational logic: mechanisms validated in genetically defined high-risk cohorts often illuminate cancer biology applicable to sporadic malignancies. If liquid biopsy sensitivity matures alongside polygenic risk stratification, the prevention-interception model piloted in CPS could eventually extend to population-level cancer control.